Literature DB >> 27805253

Cortactin contributes to the tumorigenicity of colorectal cancer by promoting cell proliferation.

Huo Wu1, Xi Cheng1, Xiaopin Ji1, Yonggang He1, Xiaoqian Jing1, Haoxuan Wu1, Ren Zhao1.   

Abstract

Cortactin is a scaffolding protein that regulates Arp2/3-mediated actin polymerization. We showed in a previous study that cortactin was highly expressed in human stage II-III colorectal cancer (CRC) tissues. In the present study, using colony formation and CCK-8 assays, we showed that overexpression of cortactin accelerated the proliferation of CRC cells. Flow cytometric assays revealed that cortactin promoted G1/S phase cell cycle transition. Later, we constructed the phosphorylation mutation of cortactin at the Tyr421 residue. Colony formation and CCK-8 assays showed that cortactin/Tyr421A lost its ability to promote cell proliferation. Western blot analysis indicated that cortactin activated cyclin D1, but not cortactin/Tyr421A. Further study in nude mice revealed that there was a greater decrease in both tumor volume and tumor weight in animals injected with SW480/cortactin/Tyr421A cells than in those injected with SW480/cortactin/WT cells. Thus, the present study demonstrates that the cortactin Tyr421 residue is required to promote cell proliferation both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27805253     DOI: 10.3892/or.2016.5207

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  2 in total

1.  NDRG3 facilitates colorectal cancer metastasis through activating Src phosphorylation.

Authors:  Xiangling Meng; Huo Wu; Ting Li; Ruochuan Sun; Mingdian Lu; Jiacong Chang
Journal:  Onco Targets Ther       Date:  2018-05-15       Impact factor: 4.147

2.  Hematopoietic lineage cell-specific protein 1 (HS1), a hidden player in migration, invasion, and tumor formation, is over-expressed in ovarian carcinoma cells.

Authors:  Yoshihiro Koya; Wenting Liu; Yoshihiko Yamakita; Takeshi Senga; Kiyosumi Shibata; Mamoru Yamashita; Akihiro Nawa; Fumitaka Kikkawa; Hiroaki Kajiyama
Journal:  Oncotarget       Date:  2018-08-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.